- New candidate drug molecules identified by pharmaceutical companies through AI;
- New alloy formulas discovered by material laboratories;
- Optimized circuit architectures developed by chip design teams;
- Even new products incubated by startups based on AI-generated ideas.
This will tank adoption in high tech fields that live and die by IP.
No, for every established company that may be hesitant, there's up and comer with nothing to lose who will jump on the opportunity, and the industry will continue moving forward.
These type of stories are typically attributed to anonymous sources. So it’s impossible for a reader to conclude anything about the sources’ own credibility. So they usually rely on the credibility of the reporter or media org who’s published about it.
The Information is also reporting on this, but paywalled. IMO The Information does solid reporting.
Editing to add some of the Information’s reporting:
> Speaking at a panel at Davos moderated by The Information CEO Jessica Lessin, Friar suggested that in the field of drug discovery, her company could, for instance, take a “license to the drug that is discovered” using OpenAI’s technology. In other words, OpenAI would take a profit-sharing stake in the financial upside its AI creates for customers.
> Friar is no doubt familiar with older AI drug discovery firms such as Recursion that struck deals with pharmaceutical firms to give them big bounties for successful drugs identified by their tech. There aren’t many, if any, examples of such successes yet, though.
> OpenAI isn’t the only firm eyeing this opportunity. Its rivals Anthropic, Google DeepMind and Isomorphic Labs, an Alphabet subsidiary focusing on using AI for drug discovery, have also held discussions with early-stage biotechnology startups about data licensing or partnerships.
This is like book publishers asking to take a slice of your income due to presenting you with the information you studied to become proficient. Except the book publishers actually helped to create the information that helped you and didn't steal it.
People are way misinterpreting OpenAI’s intentions here. The idea is that OpenAI could propose to enter into joint ventures with industry partners where each side gets a share of the rewards generated by the joint activity. This is would only happen in the cases where it’s an attractive proposition to both sides.
From the pharma side, I have heard discussions with other technology companies who insisted on a share of discovery revenue. Nothing has ever killed discussions so quickly.
> Your business model might end up being sort of a … startup incubator or private equity firm; you’d spend your time starting or acquiring companies on which the robot could work its magic. Your business model would be “general business, but with AI”.. Either it will sell AI at high margins to lots of businesses, or it will sell AI at lower margins to lucrative businesses that it owns.
Oh boy, I imagine a number of companies would drop Open AI usage altogether if the terms change to say OpenAI now gets a cut of the profit from anything created from using AI. This is crazy and wouldn't need to be possible if they already had a profitable business model. Imagine other companies like Microsoft or Apple charging companies a 'technology empowerment fee' because you used Windows or Mac computers to create something.
3eb7988a1663 | a day ago
anilgulecha | 20 hours ago
This is not a capability that will go unused.
dsr_ | a day ago
Instead, it's advertising and speculation.
cbracketdash | a day ago
[OP] jpster | 22 hours ago
The Information is also reporting on this, but paywalled. IMO The Information does solid reporting.
https://www.theinformation.com/newsletters/applied-ai/openai...
Editing to add some of the Information’s reporting: > Speaking at a panel at Davos moderated by The Information CEO Jessica Lessin, Friar suggested that in the field of drug discovery, her company could, for instance, take a “license to the drug that is discovered” using OpenAI’s technology. In other words, OpenAI would take a profit-sharing stake in the financial upside its AI creates for customers.
> Friar is no doubt familiar with older AI drug discovery firms such as Recursion that struck deals with pharmaceutical firms to give them big bounties for successful drugs identified by their tech. There aren’t many, if any, examples of such successes yet, though.
> OpenAI isn’t the only firm eyeing this opportunity. Its rivals Anthropic, Google DeepMind and Isomorphic Labs, an Alphabet subsidiary focusing on using AI for drug discovery, have also held discussions with early-stage biotechnology startups about data licensing or partnerships.
grammarxcore | 17 hours ago
TheHideout | a day ago
maxerickson | 23 hours ago
tylerchilds | 23 hours ago
teeray | 22 hours ago
dfajgljsldkjag | 23 hours ago
gmd63 | 23 hours ago
changoplatanero | 23 hours ago
fullshark | 23 hours ago
3eb7988a1663 | 23 hours ago
changoplatanero | 23 hours ago
jasfi | 20 hours ago
mikeaskew4 | 23 hours ago
fullshark | 23 hours ago
cluckindan | 23 hours ago
lachlan_gray | 23 hours ago
palmotea | 19 hours ago
No. You see, the money is supposed to go to Altman.
plagiarist | 23 hours ago
walterbell | 23 hours ago
> Your business model might end up being sort of a … startup incubator or private equity firm; you’d spend your time starting or acquiring companies on which the robot could work its magic. Your business model would be “general business, but with AI”.. Either it will sell AI at high margins to lots of businesses, or it will sell AI at lower margins to lucrative businesses that it owns.
Driver4732 | 10 hours ago